Clinical trials: Chronic Hepatitis C
Hepatitis C, Chronic, Hepatitis C
Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative.
The goal of this monocentric prospective observational study is to evaluate the prevalence of unknown hepatitis C virus chronic infection in general population born before january 1st 1968 in Italy.
- Conditions
- Hepatitis C, Chronic, Hepatitis C, Hepatitis
- Trial name
- ERADIcATE (NCT05813691)
- Testing
- Meridan Bioscience Point of Care test against HCV antibodies
- Volunteers
- 4,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Kidney Failure, Hepatitis C
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
This is a single center study characterizing the experience of administration of 4 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor…
- Conditions
- Kidney Failure, Hepatitis C, Kidney Disease, Chronic
- Trial name
- QUICK-CURE (NCT04515797)
- Testing
- Glecaprevir and Pibrentasvir
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
HIV Infections, Chronic Hepatitis C
Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients
The purpose of this pilot study is to evaluate efficacy and safety of addition of IL-2 to pegylated interferon alpha 2a and ribavirin in HIV-HCV coinfected patients non-responders after three months of standard therapy with…
- Trial name
- NCT00196586
- Testing
- Interleukin 2, pegylated interferon alpha 2a, ribavirin
- Where
- France
- Volunteers
- 75 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, Hepatitis B, Chronic
Laboratory Profile of Hepatitis B and C in Users of a Reference Service
Chronic hepatitis by the B virus (HBV) and/or by the C virus (HCV) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a…
- Trial name
- NCT00512941
- Where
- 2 sites in Brazil
- Volunteers
- 531 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Hepatitis C Virus Infection
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants…
- Trial name
- NCT02994056
- Testing
- SOF/VEL, RBV
- Where
- 12 sites in United States, France
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a…
- Trial name
- NCT00062816
- Testing
- ISIS 14803, peginterferon alfa, ribavirin
- Where
- 25 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hepatitis C, Chronic
Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy
The present study evaluates neurocognitive performance as well as measures of mood, quality of life, and fatigue in patients with chronic hepatitis C infection.
- Trial name
- IFNfreeCOG (NCT02469012)
- Testing
- Combination #1, Combination #2, Combination #3
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Wuerzburg
Chronic Hepatitis C
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV.
- Trial name
- NCT01377909
- Testing
- statin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bader, Ted, M.D.
Hepatitis C, Chronic
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or…
- Trial name
- NCT01366638
- Testing
- TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), Ribavirin (RBV)
- Where
- 11 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hepatitis, Chronic Active
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in…
- Trial name
- NCT00277238
- Testing
- CPG10101, Control
- Where
- 14 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
Chronic Hepatitis C Infection, Compensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir)…
- Trial name
- TURQUOISE-II (NCT01704755)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Volunteers
- 381 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, Chronic
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
the aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 24-48 weeks, according to re-randomisation of Early Treatment Success (ETS) patients…
- Trial name
- NCT01399619
- Testing
- PegIFN/RBV, BI201335, BI201335 24W
- Where
- 71 sites in United States, Brazil and 6 more
- Volunteers
- 310 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)
This study will assess the efficacy of boceprevir (BOC) in combination with PegIntron (pegylated interferon alfa-2b) (PEG) and ribavirin (RBV) in response guided therapy compared to the efficacy of standard-of-care therapy alone…
- Trial name
- NCT01390844
- Testing
- Boceprevir (BOC), Peginterferon alfa-2b (PEG), Ribavirin (RBV)
- Volunteers
- 282 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and…
- Trial name
- D-LITE (NCT01309932)
- Testing
- Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV)
- Where
- 40 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects
The purpose of this study is to compare PEG-interferon alfa-2b and two different doses of rivavirin for the treatment of chronic hepatitis C in previously untreated adult subjects
- Trial name
- NCT00299936
- Testing
- Ribavirin, PEG-Intron
- Volunteers
- 5,000 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Hepatitis C
Pharmacogenomic Research in Korean Patients With Hepatitis C
The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV).
- Trial name
- NCT01453244
- Where
- South Korea
- Volunteers
- 373 people
- Sponsor
- Inje University
Chronic Hepatitis C
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Rationale: Chronic HCV infection is characterised by a weak HCV specific CD8+ T cell response, due to continuous pressure of high viral load.
- Trial name
- ImmunoDual (NCT02282709)
- Testing
- Daclatasvir, asunaprevir
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Foundation for Liver Research
Hepatitis C
The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC
The purpose of this study is to determine if administering Mogroside Sweetener "PureLo" (the study substance) for 14 days will lower the hepatitis C viral load and liver function alanine aminotransferase (ALT) levels.
- Trial name
- PureLo (NCT00926120)
- Testing
- Mogroside sweetener (PureLo)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brooke Army Medical Center
Hepatitis C, Chronic, Heart Failure
Hepatitis C Virus(HCV) Heart and Lung Study
This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.
- Conditions
- Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
- Trial name
- NCT02858180
- Testing
- Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Hepatitis C Virus
Ph IIA Study (SOC +/- NS5B)
At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the treatment of treatment-naïve, chronically-infected…
- Trial name
- HEPCAT (NCT01193361)
- Testing
- BMS-791325, Peg-interferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb